Peter Borchmann, MD, University Hospital Cologne, Cologne, Germany, discusses an investigation within the Phase III HD17 trial (NCT01356680) of the prognostic impact of PET status on progression-free survival (PFS) in patients with Hodgkin lymphoma (HL) previously treated with 2+2 chemotherapy. The study of over 900 patients found that in early-stage unfavorable HL, a positive PET scan represents a risk factor for PFS, particularly when a Deauville score (DS) of 4 is considered as the cutoff for positivity. Since bulky disease after chemotherapy is a risk factor for DS4, further research is needed into early identification of these high-risk patients in order to improve the treatment strategy. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.